The relative benefits of oral and intravenous fluoropyrimidines in the palliative treatment of colo-rectal cancer are uncertain. Large studies have suggested that response rates to the oral fluoropyrimidines are higher and that the oral agents are better

This review has been withdrawn.

The reason for withdrawal and previous versions are archived and accessible within the withdrawn record in the Cochrane Library.